1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Ismail NI, Kaur G, Hashim H and Hassan MS:
S100A4 overexpression proves to be independent marker for breast
cancer progression. Cancer Cell Int. 8:122008. View Article : Google Scholar : PubMed/NCBI
|
3
|
Fedewa SA, Sauer AG, Siegel RL and Jemal
A: Prevalence of major risk factors and use of screening tests for
cancer in the United States. Cancer Epidemiol Biomarkers Prev.
26:1192–1208. 2017. View Article : Google Scholar
|
4
|
Zou DH, He XM, Chen B, Xu XH, Zhang XP, Ni
JF and Mao WM: Expression and association of reproductive hormones
and receptors in postmenopausal patients with breast cancer. Eur J
Gynaecol Oncol. 38:727–732. 2017.
|
5
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
6
|
Rivera E and Gomez H: Chemotherapy
resistance in metastatic breast cancer: The evolving role of
ixabepilone. Breast Cancer Res. 12(Suppl 2): S22010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Lorusso G and Rüegg C: The tumor
microenvironment and its contribution to tumor evolution toward
metastasis. Histochem Cell Biol. 130:1091–1103. 2008. View Article : Google Scholar : PubMed/NCBI
|
8
|
Gromak N: Intronic microRNAs: A crossroad
in gene regulation. Biochem Soc Trans. 40:759–761. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Fernandez S, Risolino M, Mandia N, Talotta
F, Soini Y, Incoronato M, Condorelli G, Banfi S and Verde P:
miR-340 inhibits tumor cell proliferation and induces apoptosis by
targeting multiple negative regulators of p27 in non-small cell
lung cancer. Oncogene. 34:3240–3250. 2015. View Article : Google Scholar
|
10
|
Sandhu R, Rein J, D’Arcy M, Herschkowitz
JI, Hoadley KA and Troester MA: Overexpression of miR-146a in
basal-like breast cancer cells confers enhanced tumorigenic
potential in association with altered p53 status. Carcinogenesis.
35:2567–2575. 2014. View Article : Google Scholar : PubMed/NCBI
|
11
|
Waning DL, Mohammad KS and Guise TA:
Cancer-associated osteoclast differentiation takes a good look in
the miR(NA)ror. Cancer Cell. 24:407–409. 2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Valeri N, Braconi C, Gasparini P, Murgia
C, Lampis A, Paulus-Hock V, Hart JR, Ueno L, Grivennikov SI, Lovat
F, et al: MicroRNA-135b promotes cancer progression by acting as a
downstream effector of oncogenic pathways in colon cancer. Cancer
Cell. 25:469–483. 2014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Ma Y, Zhang P, Wang F, Zhang H, Yang Y,
Shi C, Xia Y, Peng J, Liu W, Yang Z and Qin H: Elevated oncofoetal
miR-17-5p expression regulates colorectal cancer progression by
repressing its target gene P130. Nat Commun. 3:12912012. View Article : Google Scholar : PubMed/NCBI
|
14
|
Wang B, Wang H and Yang Z: MiR-122
inhibits cell proliferation and tumorigenesis of breast cancer by
targeting IGF1R. PLoS One. 7:e470532012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Li L, Yuan L, Luo J, Gao J, Guo J and Xie
X: MiR-34a inhibits proliferation and migration of breast cancer
through down-regulation of Bcl-2 and SIRT1. Clin Exp Med.
13:109–117. 2013. View Article : Google Scholar
|
16
|
Sun Y, Wang M, Lin G, Sun S, Li X, Qi J
and Li J: Serum microRNA-155 as a potential biomarker to track
disease in breast cancer. PLoS One. 7:e470032012. View Article : Google Scholar :
|
17
|
Nagel R, le Sage C, Diosdado B, van der
Waal M, Oude Vrielink JA, Bolijn A, Meijer GA and Agami R:
Regulation of the adenomatous polyposis coli gene by the miR-135
family in colorectal cancer. Cancer Res. 68:5795–5802. 2008.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Holleman A, Chung I, Olsen RR, Kwak B,
Mizokami A, Saijo N, Parissenti A, Duan Z, Voest EE and Zetter BR:
miR-135a contributes to paclitaxel resistance in tumor cells both
in vitro and in vivo. Oncogene. 30:4386–4398. 2011. View Article : Google Scholar : PubMed/NCBI
|
19
|
Yamada Y, Hidaka H, Seki N, Yoshino H,
Yamasaki T, Itesako T, Nakagawa M and Enokida H: Tumor-suppressive
microRNA-135a inhibits cancer cell proliferation by targeting the
c-MYC oncogene in renal cell carcinoma. Cancer Sci. 104:304–312.
2013. View Article : Google Scholar
|
20
|
Chen Y, Zhang J, Wang H, Zhao J, Xu C, Du
Y, Luo X, Zheng F, Liu R, Zhang H and Ma D: miRNA-135a promotes
breast cancer cell migration and invasion by targeting HOXA10. BMC
Cancer. 12:1112012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Xu B, Tao T, Wang Y, Fang F, Huang Y, Chen
S, Zhu W and Chen M: hsa-miR-135a-1 inhibits prostate cancer cell
growth and migration by targeting EGFR. Tumour Biol.
37:14141–14151. 2016. View Article : Google Scholar : PubMed/NCBI
|
22
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–190. 2009. View Article : Google Scholar : PubMed/NCBI
|
23
|
Xu WH, Liu ZB, Yang C, Qin W and Shao ZM:
Expression of dickkopf-1 and beta-catenin related to the prognosis
of breast cancer patients with triple negative phenotype. PLoS One.
7:e376242012. View Article : Google Scholar : PubMed/NCBI
|
24
|
Lópezknowles E, Zardawi SJ, McNeil CM,
Millar EK, Crea P, Musgrove EA, Sutherland RL and O’Toole SA:
Cytoplasmic localization of beta-catenin is a marker of poor
outcome in breast cancer patients. Cancer Epidemiol Biomarkers
Prev. 19:301–309. 2010. View Article : Google Scholar
|
25
|
Zardawi SJ, O’Toole SA, Sutherland RL and
Musgrove EA: Dysregulation of Hedgehog, Wnt and Notch signalling
pathways in breast cancer. Histol Histopathol. 24:385–398.
2009.PubMed/NCBI
|
26
|
He X: Understanding Wnt/b-catenin
signaling in development and cancer. J Nanjing Med Univ.
22:802008.
|
27
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
28
|
Chen Q, Cao HZ and Zheng PS: LGR5 promotes
the proliferation and tumor formation of cervical cancer cells
through the Wnt/β-catenin signaling pathway. Oncotarget.
5:9092–9105. 2014.PubMed/NCBI
|
29
|
Hua HW, Jiang F, Huang Q, Liao Z and Ding
G: MicroRNA-153 promotes Wnt/β-catenin activation in hepatocellular
carcinoma through suppression of WWOX. Oncotarget. 6:3840–3847.
2015. View Article : Google Scholar : PubMed/NCBI
|
30
|
Zhou DS, Wang HB, Zhou ZG, Zhang YJ, Zhong
Q, Xu L, Huang YH, Yeung SC, Chen MS and Zeng MS: TACC3 promotes
stemness and is a potential therapeutic target in hepatocellular
carcinoma. Oncotarget. 6:24163–24177. 2015. View Article : Google Scholar : PubMed/NCBI
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
32
|
Zhang B, Wang Q and Pan X: MicroRNAs and
their regulatory roles in animals and plants. J Cell Physiol.
210:279–289. 2007. View Article : Google Scholar
|
33
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Ann Rev Med. 60:167–179. 2015. View Article : Google Scholar
|
34
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-C ordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
35
|
Miranda KC, Huynh T, Tay Y, Ang YS, Tam
WL, Thomson AM, Lim B and Rigoutsos I: A pattern-based method for
the identification of MicroRNA binding sites and their
corresponding heteroduplexes. Cell. 126:1203–1217. 2006. View Article : Google Scholar : PubMed/NCBI
|
36
|
Shi W, Gerster K, Alajez NM, Tsang J,
Waldron L, Pintilie M, Hui AB, Sykes J, P’ng C, Miller N, et al:
MicroRNA-301 mediates proliferation and invasion in human breast
cancer. Cancer Res. 71:2926–2937. 2011. View Article : Google Scholar : PubMed/NCBI
|
37
|
Wu H, Huang M, Cao P, Wang T, Shu Y and
Liu P: MiR-135a targets JAK2 and inhibits gastric cancer cell
proliferation. Cancer Biol Ther. 13:281–288. 2012. View Article : Google Scholar : PubMed/NCBI
|
38
|
Bar-Or A, Nuttall RK, Duddy M, Alter A,
Kim HJ, Ifergan I, Pennington CJ, Bourgoin P, Edwards DR and Yong
VW: Analyses of all matrix metalloproteinase members in leukocytes
emphasize monocytes as major inflammatory mediators in multiple
sclerosis. Brain. 126:2738–2749. 2003. View Article : Google Scholar : PubMed/NCBI
|
39
|
Westermarck J and Kähäri VM: Regulation of
matrix metalloproteinase expression in tumor invasion. FASEB J.
13:781–792. 1999. View Article : Google Scholar : PubMed/NCBI
|
40
|
Kraiem Z and Korem S: Matrix
metalloproteinases and the thyroid. Thyroid. 10:1061–1069. 2000.
View Article : Google Scholar
|
41
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:14202009.
View Article : Google Scholar : PubMed/NCBI
|
42
|
Kalluri R and Neilson EG:
Epithelial-mesenchymal transition and its implications for
fibrosis. J Clin Invest. 112:1776–1784. 2003. View Article : Google Scholar : PubMed/NCBI
|
43
|
Leung CO, Mak WN, Kai AK, Chan KS, Lee TK,
Ng IO and Lo RC: Sox9 confers stemness properties in hepatocellular
carcinoma through Frizzled-7 mediated Wnt/β-catenin signaling.
Oncotarget. 7:29371–29386. 2016. View Article : Google Scholar : PubMed/NCBI
|
44
|
Yuan X, Sun X, Shi X, Wang H, Wu G, Jiang
C, Yu D, Zhang W, Xue B and Ding Y: USP39 promotes colorectal
cancer growth and metastasis through the Wnt/β-catenin pathway.
Oncol Rep. 37:2398–2404. 2017. View Article : Google Scholar : PubMed/NCBI
|
45
|
Mao Y, Xu J, Li Z, Zhang N, Yin H and Liu
Z: The role of nuclear β-catenin accumulation in the Twist2-induced
ovarian cancer EMT. PLoS One. 8:e782002013. View Article : Google Scholar
|
46
|
Yamamoto Y and Gaynor RB: Therapeutic
potential of inhibition of the NF-κB pathway in the treatment of
inflammation and cancer. J Clin Invest. 107:135–142. 2001.
View Article : Google Scholar : PubMed/NCBI
|
47
|
Takaesu G, Surabhi RM, Park KJ,
Ninomiya-Tsuji J, Matsumoto K and Gaynor RB: TAK1 is critical for
IkappaB kinase-mediated activation of the NF-kappaB pathway. J Mol
Biol. 326:105–115. 2003. View Article : Google Scholar : PubMed/NCBI
|
48
|
Sasaki CY, Barberi TJ, Ghosh P and Longo
DL: Phosphorylation of RelA/p65 on serine 536 defines an
I{kappa}B{alpha}-independent NF-{kappa}B pathway. J Biol Chem.
280:34538–34547. 2005. View Article : Google Scholar : PubMed/NCBI
|
49
|
Wajant H and Scheurich P: TNFR1-induced
activation of the classical NF-κB pathway. FEBS J. 278:862–876.
2015. View Article : Google Scholar
|